Recent Publications by CFE Educators
Recent Published articles, books, and other scholarship by Academy members, CFE Education Scientists, and CFE Faculty.
The association of TNF inhibitor use with incident cardiovascular events in radiographic axial spondyloarthritis.
2024
Authors: Liew JW, Treu T, Park Y, Ferguson JM, Rosser MA, Ho YL, Gagnon DR, Stovall R, Monach P, Heckbert SR, Gensler LS, Liao KP, Dubreuil M
BACKGROUND
Whether tumor necrosis factor inhibitor (TNFi) use is cardioprotective among individuals with radiographic axial spondyloarthritis (r-axSpA), who have heightened cardiovascular (CV) risk, is unclear. We tested the association of TNFi use with incident CV outcomes in r-axSpA.
METHODS
We identified a r-axSpA cohort within a Veterans Affairs database between 2002 and 2019 using novel phenotyping methods and secondarily using ICD codes. TNFi use was assessed as a time-varying exposure using pharmacy dispense records. The primary outcome was incident CV disease identified using ICD codes for coronary artery disease, myocardial infarction or stroke. We fit Cox models with inverse probability weights to estimate the risk of each outcome with TNFi use versus non-use. Analyses were performed in the overall cohort, and separately in two periods (2002-2010, 2011-2019) to account for secular trends.
RESULTS
Using phenotyping we identified 26,928 individuals with an r-axSpA diagnosis (mean age 63.4 years, 94 % male); at baseline 3633 were TNFi users and 23,295 were non-users. During follow-up of a mean 3.3 ± 4.2 years, 674 (18.6 %) TNFi users had incident CVD versus 11,838 (50.8 %) non-users. In adjusted analyses, TNFi use versus non-use was associated with lower risk of incident CVD (HR 0.34, 95 % CI 0.29-0.40) in the cohort overall, and in the two time periods separately.
CONCLUSION
In this r-axSpA cohort identified using phenotyping methods, TNFi use versus non-use had a lower risk of incident CVD. These findings provide reassurance regarding the CV safety of TNFi agents for r-axSpA treatment. Replication of these results in other cohorts is needed.
View on PubMedAssociation of Pediatric Postcardiac Arrest Ventilation and Oxygenation with Survival Outcomes.
2024
Authors: Frazier AH, Topjian AA, Reeder RW, Morgan RW, Fink EL, Franzon D, Graham K, Harding ML, Mourani PM, Nadkarni VM, Wolfe HA, Ahmed T, Bell MJ, Burns C, Carcillo JA, Carpenter TC, Diddle JW, Federman M, Friess SH, Hall M, Hehir DA, Horvat CM, Huard LL, Maa T, Meert KL, Naim MY, Notterman D, Pollack MM, Schneiter C, Sharron MP, Srivastava N, Viteri S, Wessel D, Yates AR, Sutton RM, Berg RA
POS0806 LONG-TERM SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB ACROSS THE FULL SPECTRUM OF AXIAL SPONDYLOARTHRITIS: 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES.
2024
Authors: X. Baraliakos, A. Deodhar, D. Van der Heijde, F. Van den Bosch, M. Magrey, W.P. Maksymowych, T. Tomita, H. Xu, U. Massow, C. Fleurinck, T. Vaux, C. Prajapati, J. Shepherd-Smith, A. Marten, L.S. Gensler
POS0391 THE MSQUASH AS MEASUREMENT TOOL FOR DAILY PHYSICAL ACTIVITY: TRANSLATION AND CROSS-CULTURAL ADAPTATION INTO ENGLISH, FIELD-TESTING IN DIFFERENT RHEUMATIC DISEASES AND CLINICAL VALIDATION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS.
2024
Authors: Y.M. Van der Kraan, L.S. Gensler, D. Paap, E. Thovmasyan, N.S. Ausma, H. Kokol, M. Carbo, K. De Leeuw, K. Van der Geest, H. Bootsma, J.P.L. Spoorenberg, S. Arends
POS0215 LONG-TERM SAFETY AND EFFICACY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 5-YEAR RESULTS FROM A PHASE 2B STUDY AND ITS OPEN-LABEL EXTENSION.
2024
Authors: A. Deodhar, V. Navarro-Compán, D. Poddubnyy, L.S. Gensler, S. Ramiro, T. Tomita, H. Marzo-Ortega, C. Fleurinck, T. Vaux, U. Massow, D. Van der Heijde, X. Baraliakos
POS0194 FACTORS ASSOCIATED WITH RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS RECEIVING IL-17A INHIBITOR OR TNF INHIBITOR THERAPY: A POST-HOC ANALYSIS OF THE SURPASS STUDY.
2024
Authors: D. Poddubnyy, J. Braun, P. Machado, V. Navarro-Compán, L.S. Gensler, K.G. Hermann, E. Quebe-Fehling, C.C. Pieterse, A. Readie, C. Gaillez, X. Baraliakos
AB0913 EFFICACY OF CERTOLIZUMAB PEGOL IN PREVENTING ANTERIOR UVEITIS FLARES COMPARED WITH STANDARD NON-BIOLOGIC TREATMENT: A MATCHED CONTROL STUDY IN HIGH-RISK PATIENTS WITH AXIAL SPONDYLOARTHRITIS.
2024
Authors: N. Haroon, Z. Baskurt, T. Chim, R. Inman, D. Paez, T. Kumke, R. Tham, M. Kim, I. Van der Horst-Bruinsma, L.S. Gensler
AB0881 LONG-TERM SAFETY AND TOLERABILITY OF BIMEKIZUMAB IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM POOLED PHASE 2B/3 STUDIES.
2024
Authors: P.J. Mease, D. Poddubnyy, A.M. Orbai, R.B. Warren, C. Fleurinck, R. Bajracharya, B. Ink, U. Massow, V. Shende, J. Shepherd-Smith, L. Peterson, K. White, R. Landewé, L.S. Gensler
AB1467 EFFECTIVENESS OF TELEMEDICINE IN RHEUMATOLOGY: A MULTI-SITE RANDOMIZED, SINGLE-BLIND, PARALLEL GROUP, NONINFERIORITY TRIAL IN THE UNITED STATES.
2024
Authors: L. Jackson, J. Leach, J. Yazdany, K. Saag, J.R. Curtis, D. Paez, S. Goglin, M. Margaretten, D. Chae, G. Cutter, M. Danila
Ambulatory Blocks in Pulmonary and Critical Care Fellowship Reprioritize Outpatient Medicine.
2024
Authors: Witt LJ, Heath JK
